A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC)
Status:
Not yet recruiting
Trial end date:
2024-07-30
Target enrollment:
Participant gender:
Summary
This is a phase 1b, multicenter, open label, single arm study designed to evaluate the
efficacy, safety, tolerability, pharmacokinetic (PK), and immunogenicity of QL1706 plus
lenvatinib in subjects with advanced RCC.